Drugs / [F-18]FBR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00527579 | Sep 2007 → Nov 2013 | cysticercosis | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]FBR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00527579 ↗ |
| Known as | N-fluroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline | “Recently we developed a new ligand, N-fluroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline (\[(18)F\]FBR), which showed much greater specific signals than \[(11) C\]PK11195 in...” NCT00527579 ↗ |
| Modality | Diagnostic / imaging agent | “PET Imaging” NCT00527579 ↗ |